Viking Therapeutics (VKTX) Projected to Post Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is projected to announce its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Viking Therapeutics Stock Performance

Shares of NASDAQ:VKTX opened at $29.92 on Tuesday. The stock has a market capitalization of $3.38 billion, a price-to-earnings ratio of -14.11 and a beta of 0.76. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $43.15. The company has a 50 day moving average price of $34.45 and a 200 day moving average price of $32.83.

Insiders Place Their Bets

In other Viking Therapeutics news, CFO Greg Zante sold 57,661 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $32.90, for a total transaction of $1,897,046.90. Following the completion of the sale, the chief financial officer directly owned 189,891 shares in the company, valued at approximately $6,247,413.90. This trade represents a 23.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Marianna Mancini sold 57,661 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $32.98, for a total value of $1,901,659.78. Following the completion of the transaction, the chief operating officer owned 409,190 shares in the company, valued at $13,495,086.20. This represents a 12.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 364,731 shares of company stock valued at $12,053,627 in the last 90 days. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Viking Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VKTX. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Viking Therapeutics by 29.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,109 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 481 shares during the period. Banque Cantonale Vaudoise raised its holdings in shares of Viking Therapeutics by 16.7% during the third quarter. Banque Cantonale Vaudoise now owns 3,752 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 536 shares in the last quarter. Parallel Advisors LLC boosted its position in Viking Therapeutics by 167.0% during the third quarter. Parallel Advisors LLC now owns 4,854 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 3,036 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Viking Therapeutics by 307.6% during the second quarter. Tower Research Capital LLC TRC now owns 6,974 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 5,263 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in Viking Therapeutics in the second quarter valued at about $196,000. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Wall Street Analysts Forecast Growth

VKTX has been the subject of several research reports. Morgan Stanley raised their price objective on Viking Therapeutics from $98.00 to $102.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. JPMorgan Chase & Co. decreased their price target on Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating for the company in a research report on Friday, October 24th. Canaccord Genuity Group lifted their price target on Viking Therapeutics from $106.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. B. Riley upgraded Viking Therapeutics to a “strong-buy” rating in a report on Thursday, October 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Viking Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $87.14.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.